Progress of clinical pharmacological study on rifabutin
- VernacularTitle:利福霉素衍生物Rifabutin的临床药理研究进展
- Author:
Zhaoxu LI
;
Jinnan ZHANG
;
Shuang REN
;
Chengying GAO
;
Yi SUN
- Publication Type:Journal Article
- Keywords:
Rifabutin;
CYP450;
drug interaction;
MAC;
pulmonary tuberculosis;
Helicobacter pylori
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2000;0(01):-
- CountryChina
- Language:Chinese
-
Abstract:
Rifabutin(RBT) is a rifamycin derivative,like rifampicin(RIF),registered for the prophylaxis and treatment of mycobacterium avium complex (MAC)in patients with AIDS by FDA in 1992.Subsequently,the drug was approved by many other countries.But now,it is used not only in the prophlaxis and treatment of mycobacterium avium complex but also in the treatment of pulmonary tuberculosis and Helicobacter pylori.For its high lipophilic characteristic and weak inducing properties compare to other rifamycin derivative,it can be applied in treatment with many diseases successfully,especially when combine with other antibiotics,and can solve the problem of traditional antibiotics resistance and increase the clinical safety of combined medical treatment.This paper just shows the progress of clinical pharmacological study and related aspects on rifabutin in order to instruct prescription.
